Hierroquick

Quick links to important sections

Hierroquick

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hierroquick

Property Description
Active Ingredients Elemental Iron and Folic Acid (Vitamin B9)
Form Oral Tablet (Coated/Film-Coated)
Pharmacological Class Haematinic Agents (Antianemic Agents)
General Purpose Correcting combined iron and folate deficiencies
Origin Synthetic (Mineral and B-vitamin)

What Type of Medicine is Hierroquick? (Identity and Classification)

Hierroquick is a combination medicine that is formally classified as an Antianemic Agent, falling within the broad pharmacological category of Haematinic Agents. This systemic preparation is specifically designed to address dual nutritional deficiencies crucial for blood production. The classification as a Haematinic Agent indicates its primary role in increasing the haemoglobin concentration and the number of red blood cells in the bloodstream. This formulation stands apart from monotherapies by combining both mineral and vitamin support in a single product, targeting the two most common simultaneous nutritional bottlenecks that impair the process of erythropoiesis (red blood cell production).


What is Hierroquick Made Of and What Form Does it Take? (Composition and Form)

Hierroquick is composed of two primary active ingredients [INN]: a source of Elemental Iron and Folic Acid, which is the synthetic form of the water-soluble B-group vitamin Folate (Vitamin B9). The iron component is derived from a ferrous salt, and the Folic Acid component is essential for the synthesis of DNA and other genetic material, a function critical for rapid cell division. The medicine is manufactured as an Oral Tablet, typically featuring a film or polymer coating, which represents the preparation's stable solid dosage form allowing for oral administration and systemic absorption into the body. This coating is often incorporated to enhance tolerability of the Elemental Iron in the gastrointestinal tract.


What is the General Purpose of This Combination? (High-Level Function)

The general therapeutic purpose of Hierroquick is to support the body's entire cycle of red blood cell maturation and to restore adequate oxygen-carrying capacity in the blood. The Elemental Iron component is critical because iron is an essential component of haemoglobin, the protein that transfers oxygen from the lungs to the tissues. Simultaneously, the Folic Acid acts as a necessary cofactor for the rapid cell production and synthesis required for blood cell development. By supplying both the mineral and the vitamin, the preparation addresses the nutritional foundation needed to alleviate general weakness and fatigue often associated with these combined nutrient deficits.

Regulatory References

  1. Haematinic Agents
  2. erythropoiesis
  3. B-group vitamin Folate (Vitamin B9)
  4. DNA
  5. red blood cell maturation
  6. oxygen-carrying capacity
  7. essential component of haemoglobin
  8. cofactor
  9. Elemental Iron
  10. Anemia
  11. Folic Acid Supplementation

What side effects are possible with Hierroquick?

Possible side effects and safety information

The official safety information for this combination medicine is organized by the frequency and physiological system of documented adverse reactions, strictly derived from regulatory labeling.

Adverse Reaction Scope

Classification System-Organ Class Documented Effects
Common Gastrointestinal Disorders Nausea, vomiting, abdominal discomfort or pain, heartburn, constipation, or diarrhea.
Rare Immune System Disorders Anaphylactic reaction, severe hypersensitivity, angioedema, and bronchospasm.
Expected Gastrointestinal Disorders Darkening of the stool (black or dark green coloration) is an expected effect due to iron excretion and is not considered harmful.

Serious Safety Considerations

Regulatory documents highlight two primary serious concerns. Anaphylactic reactions are classified as rare but potentially severe hypersensitivity events. Furthermore, the FDA mandates a prominent warning on all solid oral iron-containing products due to the established risk that accidental overdose is a leading cause of fatal poisoning in children under the age of six.

Safety-Related Restrictions

This medicine is contraindicated and should not be used in individuals with conditions of iron overload, such as hemochromatosis or hemosiderosis. It is also restricted in cases of non-iron deficiency anemias—specifically, the folate component may mask the hematological signs of undiagnosed pernicious anemia (Vitamin B12 deficiency).

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Hierroquick is driven by the acute toxicity of its Elemental Iron component, which is officially recognized as a serious medical emergency. Regulatory authorities mandate that any suspected overdose requires individuals to seek immediate medical attention.


Documented Manifestations and Severe Outcomes

Overdose typically presents with severe gastrointestinal distress, including vomiting (which may be bloody or resemble coffee grounds), severe abdominal pain, and bloody diarrhea. Systemic clinical signs documented in official labeling include excessive lethargy, pallor, tachycardia (rapid pulse), and hypotension (low blood pressure). Severe outcomes officially documented include profound metabolic acidosis, shock, hepatic failure, and central nervous system effects such as seizures and coma. Accidental overdose is a leading cause of fatal poisoning in children, underscoring the severe risk to the pediatric population.


Required Emergency Management

Contact emergency services immediately if the affected person collapses, has a seizure, or experiences difficulty breathing. Overdose management requires hospital monitoring, which includes measuring the peak serum iron level to assess toxicity. Supportive measures described in official documents include gastric decontamination (such as whole-bowel irrigation) and, in cases of severe systemic toxicity, administration of the specific antidote, Deferoxamine.

Therapeutic Uses of Hierroquick

Main Uses of Hierroquick

Hierroquick is a medicinal product designed to address iron deficiency in the body. It belongs to a group of medicines known as iron supplements. Its primary application is the treatment of iron deficiency states and iron deficiency anemia, a condition where the blood lacks adequate healthy red blood cells due to insufficient iron levels.

Iron is an essential mineral required for the production of hemoglobin, the protein in red blood cells that enables them to carry oxygen throughout the body. When iron stores are depleted, the body cannot produce enough hemoglobin, leading to various physiological symptoms.

Conditions Treated

  • Iron Deficiency Anemia: This is the most common use for Hierroquick. It is used to replenish iron stores and restore hemoglobin levels in individuals diagnosed with anemia resulting from chronic blood loss, inadequate dietary intake, or malabsorption issues.
  • Latent Iron Deficiency: In some cases, iron levels may be low even if anemia has not yet fully developed. Hierroquick may be used to treat these subclinical deficiencies to prevent the progression to clinical anemia.

Benefits and Physiological Effects

The primary benefit of Hierroquick is the restoration of normal iron levels in the body. By providing a source of supplemental iron, the medication supports several critical biological functions:

Improved Oxygen Transport

By increasing hemoglobin production, the medication helps ensure that tissues and organs receive an adequate supply of oxygen. This often results in the gradual reduction of symptoms associated with anemia, such as persistent fatigue, physical weakness, and shortness of breath during exertion.

Support for Metabolic Processes

Iron is a cofactor for numerous enzymes involved in energy metabolism and DNA synthesis. Proper iron levels contribute to more efficient cellular energy production and overall metabolic health.

Cognitive and Physical Function

Maintaining sufficient iron levels is important for cognitive performance, including concentration and memory. Additionally, adequate iron supports muscle function and the body's ability to maintain a stable internal temperature.

Regulatory References

  1. Iron Supplements: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Hierroquick, a combination of elemental iron and folic acid, is permitted for use in adults and is explicitly indicated for pregnant and lactating women for the treatment and prevention of these combined nutritional deficiencies.


Contraindicated Populations

Use of the medicine is contraindicated (must not be used) for patients with a known hypersensitivity to any ingredient, or those with iron overload disorders such as hemochromatosis or hemosiderosis. It is also prohibited for individuals with untreated Vitamin B12 deficiency (pernicious anemia), as the folic acid component can mask the neurological progression of this condition. Patients receiving repeated blood transfusions or parenteral iron therapy are also excluded.


Age and Condition Restrictions

Population Group Regulatory Status
Children under 6 years Use is subject to a mandatory fatal poisoning warning; the product must be kept out of reach. Safety is generally not established in the general pediatric population.
Gastrointestinal Disease Use requires special care in patients with a history of acute gastrointestinal disease, stomach ulcers, or colitis.
Other Anemias Contraindicated in certain types of hemolytic anemia.

What should I know about interactions with other medicines?

The interaction profile for Hierroquick (Elemental Iron and Folic Acid) is defined primarily by mechanisms that alter the systemic exposure of the active ingredients and co-administered products.

Interaction Type Interacting Substances
Contraindicated Use Undiagnosed B12 Deficiency; Dimercaprol
Absorption Interference Quinolone & Tetracycline Antibiotics; Levothyroxine; Bisphosphonates; Antacids
Metabolic/Pharmacodynamic Anticonvulsants (e.g., Phenytoin); Methotrexate
Food & Supplements Meals; Tea; Coffee; Calcium/Zinc Supplements; Ethanol

High-dose Folic Acid (above 1 mg daily) is restricted in cases of undiagnosed B12 deficiency, as official regulatory documents state it may mask hematologic signs while permitting irreversible neurological progression. Co-administration of iron with Dimercaprol is officially avoided due to the documented risk of nephrotoxicity.

The iron component reduces the systemic bioavailability of several medicines, including Tetracycline and Quinolone antibiotics, Levothyroxine, and Bisphosphonates, via chelation and pH effects. Consequently, regulatory guidance requires mandatory temporal separation of these agents, often by two to six hours. The Folic Acid component can reduce the serum concentration of certain anticonvulsant medications, such as Phenytoin, by altering their metabolic clearance. Absorption of elemental iron is significantly reduced by meals and specific beverages, notably coffee and tea. Chronic alcohol consumption is documented to increase the elimination of Folic Acid.

Mechanism of Action

How Hierroquick Works

Hierroquick operates through two synergistic substrate-replenishment mechanisms necessary for biological blood formation, which results in the combined influence on red blood cell structure and proliferation.

Enhancing Structural Integrity via Elemental Iron

This component works by acting as an essential substrate that is directly incorporated into the heme synthesis pathway in the bone marrow. Iron is required to form the haemoglobin molecule, a necessary constituent for reversible oxygen binding and release by erythrocytes. This mechanism increases the concentration of oxygen-carrying protein within red blood cell precursors.

Cofactor Function for Cell Maturation via Folic Acid

This component functions as a precursor to active cofactors, such as Tetrahydrofolate (THF), which are critical for one-carbon metabolism. This metabolic activity is essential for manufacturing the DNA bases required for cell division and nuclear maturation of the erythrocyte precursors. This mechanism supports the pathway for normal nuclear maturation and cell division, a key step in producing mature erythrocytes. The combined effect results in a mutual dependency in the pathway: Iron influences haemoglobin content, while Folic Acid influences cell proliferation, leading to the optimization of systemic oxygen-carrying capacity.

Dosage and Administration Information

Administration Guidelines

Hierroquick is an Oral Tablet containing Elemental Iron and Folic Acid. The method of intake is the oral route.

Dosing and Frequency Patterns

Dosing for the Elemental Iron component varies based on the goal of therapy. For the treatment of established deficiency, the typical dose is 100 mg to 200 mg of Elemental Iron daily. For prophylaxis or supplementation, a dose of 60 mg to 65 mg of Elemental Iron once daily is utilized. The medicine is generally scheduled for administration once daily, although the total dose may be administered in divided doses. Alternate-day dosing is also an established pattern used to enhance absorption.

Administration Conditions and Duration

To ensure proper intake, the Hierroquick tablet must be swallowed whole with water; it should not be chewed, crushed, or held in the mouth. The timing of intake is flexible: while maximum absorption occurs when taken on an empty stomach, the dose may be administered with or immediately after food to minimize potential gastrointestinal discomfort. The duration of therapy is not short-term; to fully replenish the body's iron stores, administration is typically continued for an additional period, often 10 to 20 weeks or longer, after blood values have normalized.

Population-Specific Usage

Specific parameters exist for certain groups. In pediatric patients, the treatment dosage is based on body weight, commonly 3 mg/kg to 6 mg/kg of Elemental Iron per day. During pregnancy, specific prophylactic elemental iron doses are established.

Recent Clinical Evidence

Research Evidence Overview for Hierroquick (Iron and Folic Acid)

This section provides a patient-friendly summary of the clinical research conducted for the components of Hierroquick, describing what was studied and what patterns the evidence shows, while distinguishing between established and uncertain findings.


Evidence for Correcting Iron-Deficiency Anemia and Deficiency

Research examining the use of iron and folic acid in exploring deficiencies primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies are used in research exploring deficiencies in adults who have low levels of iron or confirmed Iron-Deficiency Anemia.

Studies monitored physiological strain outcomes related to systemic imbalance by tracking haematological biomarkers, such as Haemoglobin and Ferritin levels, over defined time intervals. Findings indicate that the iron component of the medicine was studied for patterns related to changes in levels of iron and Haemoglobin. Studies report how symptoms evolved in the observed populations, where findings describe patterns observed in the studies related to changes in certain deficiency-related symptoms.


Evidence in High-Demand Populations, Including Pregnancy

The largest volume of research for this combination medicine is derived from settings involving increased need, such as pregnancy. This evidence base includes large-scale Systematic Reviews and Meta-Analyses published by major health bodies like the World Health Organization (WHO) and the Cochrane Collaboration.

Studies explored the effect of the combined supplementation in pregnant women, monitoring outcomes related to maternal anemia and infant outcomes, including the measurement of birth weight. Research highlights changes measured during the study period, where studies observed patterns related to the prevalence of maternal anemia and iron deficiency. Supplemented groups were associated with differences in average birth weight compared to control groups.


What is Still Uncertain About the Research for Hierroquick

One main uncertainty relates to comparative evidence regarding the added value of the folic acid component when used in non-pregnant adults without a documented folate deficiency. The certainty remains low for a range of less common but important maternal and infant clinical outcomes, such as patterns related to changes in preterm birth or neonatal death. Furthermore, long-term effects are not fully established regarding the sustained maintenance of iron levels after supplementation is stopped.

Key Studies & References

  1. Efficacy of a combined drug containing ferrous fumarate and folic acid in anemia in the second trimester of pregnancy

Frequently Asked Questions (FAQ)

Common questions about Hierroquick (FAQ)


Q: Is Hierroquick the same compound as an over-the-counter iron supplement?

A: Hierroquick is a combination medicine that includes Elemental Iron and Folic Acid. While Elemental Iron compounds are often found in over-the-counter supplements, this prescription-only product is specifically intended by regulatory authorities for the treatment of established dual iron and folate deficiencies. The combination formulation is key to its prescription status.


Q: What is the difference between prescription Hierroquick and common diet iron pills?

A: The main distinction lies in its use and classification. Hierroquick is formally classified as an Antianemic Agent and is prescribed for treating diagnosed deficiencies. Common diet iron pills are typically used for mild supplementation, whereas this medicine contains specific, regulated doses for a therapeutic effect on the body's nutrient levels.


Q: How does the drug purpose compare to other common iron therapies?

A: Official guidance states that the oral Elemental Iron component is considered a first-line treatment for uncomplicated iron deficiency. Other methods, such as intravenous (IV) iron, are generally reserved for individuals who cannot tolerate oral therapy or who have severe conditions that compromise the body's ability to absorb iron.


Q: How does the body's ability to absorb the active ingredient in Hierroquick compare to iron from food?

A: Labeling indicates that maximum absorption of the iron component is achieved when the medicine is taken on an an empty stomach. Taking Hierroquick with food can significantly decrease the amount of iron the body absorbs, potentially reducing absorption by 40% to 50%.


Q: Are there published clinical studies on the long-term use of Hierroquick?

A: According to official information, treatment is typically continued for an additional defined period (often about three months) after your blood levels have normalized. This is done to ensure the body's iron stores are fully replenished. Regulatory information suggests that the duration of therapy is defined by the patient's condition, and use extending beyond the established period requires medical reassessment.


Q: Are there different formulations (e.g., tablet, extended-release) available for Hierroquick?

A: The active ingredients in Hierroquick are prepared in several dosage forms. Official drug information confirms that elemental iron preparations are available in standard oral tablets, liquid solutions or drops, and special formulations such as extended-release or delayed-release tablets.


Q: What is the distinction between Hierroquick and non-prescription 'blood builder' supplements?

A: Hierroquick is classified by regulatory bodies as an Antianemic Agent, meaning its purpose is to treat diagnosed anemia. It delivers regulated doses of Elemental Iron and Folic Acid for a therapeutic effect. General non-prescription supplements may not follow the same strict standards or contain the specific combination of ingredients needed to address a diagnosed deficiency.


Q: Does taking Hierroquick require regular blood work monitoring to check iron levels?

A: Official regulatory guidance states that hemoglobin levels are monitored during therapy to assess the body's response to the medicine and track the progress toward correcting the deficiency. This process helps healthcare providers assess the body's status.


Q: How long does it typically take for Hierroquick to start working?

A: Noticeable clinical improvement in symptoms is often reported after approximately three to four weeks of consistent use. Changes in specific blood values, known as the hematologic response, may begin to be measurable even sooner, often within three to ten days.


Q: What is the expected timeline for blood test results to reflect changes after starting Hierroquick?

A: Official data indicates that key blood tests typically begin to show an increase in Hemoglobin levels within two to four weeks after starting treatment. This increase is a primary indicator of therapeutic effectiveness.


Q: Is it normal to feel no difference in symptoms after the first week of using Hierroquick?

A: Yes, it is normal not to feel an immediate difference in symptoms. Official information indicates that noticeable clinical improvement from iron supplementation usually requires consistent use for at least three to four weeks.


Q: How long do the common digestive side effects from Hierroquick typically last?

A: Common digestive side effects, such as nausea or constipation, are generally temporary. However, if these symptoms are severe or persist, official safety information notes that they should be discussed with a healthcare provider.


Q: Is there a metallic taste mentioned in the side effect profiles of Hierroquick?

A: Yes, regulatory summaries and clinical reports list a metallic taste in the mouth as a common adverse effect associated with oral iron salts. This is a recognized but temporary effect of the medicine.


Q: What types of over-the-counter pain relievers can interact with Hierroquick?

A: The folic acid component is generally considered safe to take with standard pain relievers like paracetamol (acetaminophen). However, official regulatory texts note that caution is exercised regarding NSAIDs (non-steroidal anti-inflammatory drugs) in certain circumstances due to potential interactions with other folate-related medicines.


Q: Are there any dairy products or milk that should be avoided when taking Hierroquick?

A: Official guidance states that taking Hierroquick within two hours of consuming milk or dairy products is generally avoided. This is because they contain calcium, which can significantly reduce the absorption of the elemental iron component by the body.


Q: Does Vitamin C intake influence the body's absorption of Hierroquick?

A: Yes, official drug information documents that Vitamin C (ascorbic acid) has been shown to enhance the absorption of the elemental iron component by the body. This is due to its effect on converting iron to a more readily absorbed form.


Q: Are there specific high-fiber foods that might interfere with Hierroquick?

A: Yes, certain foods can interfere with absorption. Regulatory guidance and clinical data indicate that certain high-fiber foods, as well as legumes and whole grains, contain compounds (like phytates) that can decrease the body's absorption of the elemental iron component.


Q: Are there special considerations for using Hierroquick in elderly patients?

A: Regulatory guidance suggests that lower doses of elemental iron may be effective for use in the geriatric population. Using a lower dose is also associated with a potential reduction in the incidence of common gastrointestinal side effects like nausea and constipation.


Q: Does having pre-existing kidney disease affect eligibility for Hierroquick?

A: Oral iron is often used in patients with chronic kidney disease (CKD), but its absorption can be poor. Intravenous iron is usually the preferred route for patients requiring hemodialysis, according to clinical practice guidelines.


Q: What research is available regarding Hierroquick's potential use for Restless Legs Syndrome?

A: While the medicine is officially indicated for nutritional deficiencies, scientific literature associated with its components includes data on its potential use for managing symptoms of Restless Legs Syndrome (RLS) in individuals with low iron stores.


Q: How is Hierroquick described for use in individuals who are frequent blood donors?

A: Iron supplementation is highly relevant for individuals who donate blood frequently. Official clinical summaries note that an average donation causes a substantial iron loss that can take up to 24 to 30 weeks to fully replenish without supplementation.


Q: Is there evidence-based information on Hierroquick's effectiveness in women with heavy periods?

A: The medicine is indicated for treating iron deficiency anemia, which is a condition that can be caused by chronic blood loss. This includes blood loss that may be associated with heavy menstrual periods, according to clinical etiology.

How should Hierroquick be stored and disposed of?

Official Storage and Disposal Guidelines

Regulatory agencies define the safe handling and disposal of medications to prevent accidental exposure and misuse.

Requirement Official Regulatory Statement
Child Safety Keep all medicines out of sight and reach of children and pets.
Preferred Disposal Dispose of unused or expired medicine preferably through an authorized drug take-back program or mail-back service.
Household Disposal If no take-back option is available, the medicine may be discarded into household trash. It must first be mixed with an undesirable substance (such as used coffee grounds or dirt), placed in a sealed container, and then thrown away.
Privacy Protection Scratch out all personal information on the prescription label before discarding the empty packaging.

These guidelines establish a clear disposal hierarchy and mandate secure storage to protect against accidental ingestion, which is the primary focus of the regulatory storage profile.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hierroquick found in:

A-Z Index: